dc.contributor.author | Ottestad, Anine Larsen | |
dc.contributor.author | Huang, Mo | |
dc.contributor.author | Emdal, Elisabeth Fritzke | |
dc.contributor.author | Mjelle, Robin | |
dc.contributor.author | Skarpeteig, Veronica | |
dc.contributor.author | Dai, Hong Yan | |
dc.date.accessioned | 2023-02-22T11:42:51Z | |
dc.date.available | 2023-02-22T11:42:51Z | |
dc.date.created | 2023-01-09T15:21:15Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 2075-4426 | |
dc.identifier.uri | https://hdl.handle.net/11250/3053214 | |
dc.description.abstract | (1) Background: Analysis of tumor DNA by next-generation sequencing (NGS) plays various roles in the classification and management of cancer. This study aimed to assess the performance of two similar and large, comprehensive gene panels with a focus on clinically relevant variant detection and tumor mutation burden (TMB) assessment; (2) Methods: DNA from 19 diagnostic small cell lung cancer biopsies and an AcroMetrix™ assessment sample with >500 mutations were sequenced using Oncomine™ Comprehensive Assay Plus (OCAP) on the Ion Torrent platform and TruSight Oncology 500 Assay (TSO500) on the Illumina platform; (3) Results: OCAP and TSO500 achieved comparable NGS quality, such as mean read coverage and mean coverage uniformity. A total of 100% of the variants in the diagnostic samples and 80% of the variants in the AcroMetrix™ assessment sample were detected by both panels, and the panels reported highly similar variant allele frequency. A proportion of 14/19 (74%) samples were classified in the same TMB category; (4) Conclusions: Comparable results were obtained using OCAP and TSO500, suggesting that both panels could be applied to screen patients for enrolment in personalized cancer treatment trials. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Assessment of Two Commercial Comprehensive Gene Panels for Personalized Cancer Treatment | en_US |
dc.title.alternative | Assessment of Two Commercial Comprehensive Gene Panels for Personalized Cancer Treatment | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.journal | Journal of Personalized Medicine | en_US |
dc.identifier.doi | doi.org/10.3390/jpm13010042 | |
dc.identifier.cristin | 2103494 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |